Table 3.
Clinical outcomes according to the presence of gustatory and olfactory dysfunctions in patients with COVID-19 pneumonia
| Variable | Cohort | GOD | Absence of GOD | P value |
| N | 80 | 59 | 21 | |
| LOS (IQR) | 8 (4–11.75) | 8 (4.2–11) | 7 (4–14) | 0.836 |
| SpO2/fiO2 ratio (IQR) | 448 (245–247) | 451 (257–471) | 391 (197–471) | 0.346 |
| Lopinavir/ritonavir, n (%) | 73 (94) | 52 (91) | 21 (100) | 0.161 |
| Interferon, n (%) | 6 (8) | 4 (7) | 2 (10) | 0.638 |
| Corticosteroid, n (%) | 24 (30) | 15 (3) | 9 (43) | 0.147 |
| Interleukin blocker, n (%) | 33 (41) | 22 (37) | 11 (52) | 0.228 |
| ICU admission, n (%) | 11 (14) | 7 (12) | 4 (19) | 0.412 |
| Complication n, (%) | 32 (41) | 20 (35) | 12 (57) | 0.07 |
| Oxygen requirement, n (%) | 55 (69) | 40 (68) | 15 (71) | 0.758 |
| Orotraqueal intubation, n (%) | 8 | 5 (8.5) | 3 (14) | 0.867 |
| Respiratory distress, n (%) | 31 | 20 (34) | 11 (52) | 0.135 |
| Pulmonary embolism, n (%) | 5 (6) | 0 | 5 (23) | 0.0001 |
| Organising pneumonia, n (%) | 10 (13) | 5 (9) | 5 (24) | 0.068 |
FiO2, fraction of inspired oxygen; GOD, gustatory and olfactory dysfunctions; ICU, intensive care unit; LOS, length of stay; SpO2, peripheral capillary oxygen saturation.